<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40922034</PMID><DateCompleted><Year>2025</Year><Month>09</Month><Day>08</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1475-2840</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>1</Issue><PubDate><Year>2025</Year><Month>Sep</Month><Day>08</Day></PubDate></JournalIssue><Title>Cardiovascular diabetology</Title><ISOAbbreviation>Cardiovasc Diabetol</ISOAbbreviation></Journal><ArticleTitle>Effect of Empagliflozin on the plasma lipidome in patients with type 2 diabetes mellitus: results from the EmDia clinical trial.</ArticleTitle><Pagination><StartPage>359</StartPage><MedlinePgn>359</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">359</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s12933-025-02916-0</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Sodium-glucose cotransporter 2 (SGLT2) inhibitors, such as Empagliflozin, are antidiabetic drugs that reduce glucose levels and have emerged as a promising therapy for patients with heart failure (HF), although the exact molecular mechanisms underlying their cardioprotective effects remain to be fully elucidated. The EmDia study, a randomized, double-blind trial conducted at the University Medical Center of Mainz, has confirmed the beneficial effects of Empagliflozin in HF patients after both one and twelve weeks of treatment. In this work, we aimed to assess whether changes in lipid profiles driven by Empagliflozin use in HF patients in the EmDia trial could assist in gaining a better understanding of its cardioprotective mechanisms.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Lipid analysis of blood plasma from 144 patients from the EmDia trial was conducted using 4D-LC-TIMS/IMS lipidomics. Lipid signatures after treatment for one and twelve weeks, respectively, were obtained with sparse group LASSO regularized regression models. Linear regression models were employed to highlight associations between significantly changed clinical traits and lipids.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The lipid signatures after one week of treatment consisted of 37 lipids from the lipid groups lysophosphatidylcholine (LPC), phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SM), and triacylglycerol (TG). After twelve weeks, the signature comprised 24 lipids from the same five lipid groups, along with Ceramides (Cer). Three of five lipids altered at both time points showed consistent directional trends. Empagliflozin treatment led to significant alterations in the lipidome, including increases in both beneficial lipids, such as LPCs, and potentially harmful species, notably ceramides, which have been implicated in lipotoxicity and cardiovascular risk.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study identified distinct lipid signatures associated with Empagliflozin treatment after both one and twelve weeks, respectively, with five lipids overlapping between signatures and three with consistent directions, revealing that some of the beneficial effects of Empagliflozin could be through lipid modulation. Notably, Empagliflozin-modulated lipids associated with changes in clinical traits and lipid-specific profiles among clinical subgroups were observed. However, challenges remain in establishing direct associations between&#xa0;individual lipids and clinical outcomes. Future research integrating lipidomics data with other omics datasets could provide a more comprehensive understanding of the identified lipid signatures and their potential roles in health and diseases.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">ClinicalTrials.gov; NCT02932436. Registration date, 2016/10/13.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauer</LastName><ForeName>Katrin I</ForeName><Initials>KI</Initials><AffiliationInfo><Affiliation>Computational Biomedicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Dhanwin</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Clinical Lipidomics Unit, Institute of Physiological Chemistry, University Medical Center, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lerner</LastName><ForeName>Raissa</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Lipidomics Unit, Institute of Physiological Chemistry, University Medical Center, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koeck</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buch</LastName><ForeName>Gregor</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Zlatka</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Medical Biostatistics, Epidemiology and Informatics (IMBEI), University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martens</LastName><ForeName>Robin</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Esenkova</LastName><ForeName>Ekaterina E</ForeName><Initials>EE</Initials><AffiliationInfo><Affiliation>Computational Biomedicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nuber</LastName><ForeName>Maximilian</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Computational Biomedicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andrade-Navarro</LastName><ForeName>Miguel A</ForeName><Initials>MA</Initials><AffiliationInfo><Affiliation>Institute of Organismic and Molecular Evolution, Johannes-Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ten Cate</LastName><ForeName>Vincent</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Thrombosis and Hemostasis, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tenzer</LastName><ForeName>Stefan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Immunology, University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wild</LastName><ForeName>Philipp S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Preventive Cardiology and Preventive Medicine, Department of Cardiology, University Medical Center of the Johannes-Gutenberg University Mainz, Mainz, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute for Molecular Biology (IMB), Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bindila</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Lipidomics Unit, Institute of Physiological Chemistry, University Medical Center, Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Araldi</LastName><ForeName>Elisa</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Computational Biomedicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany. araldiel@uni-mainz.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Epidemiology and Systems Medicine, Center for Thrombosis and Hemostasis (CTH), Mainz, Germany. araldiel@uni-mainz.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Cardiovascular Research (DZHK), Partner Site RhineMain, Mainz, Germany. araldiel@uni-mainz.de.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Systems Medicine Laboratory, Department of Medicine and Surgery, University of Parma, Parma, Italy. araldiel@uni-mainz.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT02932436</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>09</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cardiovasc Diabetol</MedlineTA><NlmUniqueID>101147637</NlmUniqueID><ISSNLinking>1475-2840</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>HDC1R2M35U</RegistryNumber><NameOfSubstance UI="C570240">empagliflozin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005960">Glucosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001559">Benzhydryl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000077203">Sodium-Glucose Transporter 2 Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008055">Lipids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001786">Blood Glucose</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005960" MajorTopicYN="Y">Glucosides</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001559" MajorTopicYN="Y">Benzhydryl Compounds</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003924" MajorTopicYN="Y">Diabetes Mellitus, Type 2</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077203" MajorTopicYN="Y">Sodium-Glucose Transporter 2 Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000081362" MajorTopicYN="Y">Lipidomics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008055" MajorTopicYN="Y">Lipids</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="Y">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001786" MajorTopicYN="Y">Blood Glucose</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Clinical trial</Keyword><Keyword MajorTopicYN="N">Empagliflozin</Keyword><Keyword MajorTopicYN="N">HFpEF</Keyword><Keyword MajorTopicYN="N">Lipidomics</Keyword><Keyword MajorTopicYN="N">SGLT2i</Keyword></KeywordList><CoiStatement>Declarations. Ethical approval consent to participate: The local data protection officer and the responsible ethics committee approved the study protocol [ref. no. 2018-13064] prior to study initiation. All study participants provided written informed consent prior to study enrolment. The Declaration of Helsinki [46] and the recommendations of good clinical practice and good epidemiological practice were followed in all study procedures. Consent for publication: Not applicable. Competing interests: Philipp S. Wild reports grants from Bayer AG; non-financial grants from Philips Medical Systems; grants and consulting fees from Boehringer Ingelheim, Novartis AG, Sanofi-Aventis GmbH, and Daiichi Sankyo Europe GmbH; grants and consulting and lecturing fees from Bayer Healthcare Pharmaceuticals; lecturing fees from Pfizer Inc. and Bristol Myers Squibb; consulting fees from AstraZeneca plc; consulting fees and non-financial support from DiaSorin; and non-financial support from I.E.M. Gregor Buch was employed solely at the University Medical Center Mainz during the analysis period and is currently employed by Boehringer Ingelheim. This work was not sponsored by Boehringer Ingelheim and the views of the manuscript do not represent the views of Boehringer Ingelheim. Rights and permissions: Open Access, this article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution, and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third-party material in this article are included in the article's Creative Commons license unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ .</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>11</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>8</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>34</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>9</Month><Day>9</Day><Hour>0</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>9</Month><Day>8</Day><Hour>23</Hour><Minute>24</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>9</Month><Day>8</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40922034</ArticleId><ArticleId IdType="pmc">PMC12418620</ArticleId><ArticleId IdType="doi">10.1186/s12933-025-02916-0</ArticleId><ArticleId IdType="pii">10.1186/s12933-025-02916-0</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Ference BA, Graham I, Tokgozoglu L, Catapano AL. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. J Am Coll Cardiol. 2018;72:1141&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">30165986</ArticleId></ArticleIdList></Reference><Reference><Citation>Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015. 10.1056/NEJMoa1504720.</Citation><ArticleIdList><ArticleId IdType="pubmed">26378978</ArticleId></ArticleIdList></Reference><Reference><Citation>Gevaert AB, Kataria R, Zannad F, Sauer AJ, Damman K, Sharma K, et al. Heart failure with preserved ejection fraction: recent concepts in diagnosis, mechanisms and management. Heart. 2022;108:1342&#x2013;50.</Citation><ArticleIdList><ArticleId IdType="pubmed">35022210</ArticleId></ArticleIdList></Reference><Reference><Citation>Huusko J, Tuominen S, Studer R, Corda S, Proudfoot C, Lassenius M, et al. Recurrent hospitalizations are associated with increased mortality across the ejection fraction range in heart failure. ESC Heart Fail. 2020;7:2406&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7524224</ArticleId><ArticleId IdType="pubmed">32667143</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. N Engl J Med. 2020;383:1413&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">32865377</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M, Butler J, Zannad F, Filippatos G, Ferreira JP, Pocock SJ, et al. Effect of empagliflozin on worsening heart failure events in patients with heart failure and preserved ejection fraction: EMPEROR-preserved trial. Circulation. 2021;144:1284&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8522627</ArticleId><ArticleId IdType="pubmed">34459213</ArticleId></ArticleIdList></Reference><Reference><Citation>Prochaska JH, J&#xfc;nger C, Schulz A, Arnold N, M&#xfc;ller F, Heidorn MW, et al. Effects of empagliflozin on left ventricular diastolic function in addition to usual care in individuals with type 2 diabetes mellitus&#x2014;results from the randomized, double-blind, placebo-controlled emdia trial. Clin Res Cardiol. 2023. 10.1007/s00392-023-02164-w.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10293456</ArticleId><ArticleId IdType="pubmed">36763159</ArticleId></ArticleIdList></Reference><Reference><Citation>Yaribeygi H, Sathyapalan T, Maleki M, Jamialahmadi T, Sahebkar A. Molecular mechanisms by which SGLT2 inhibitors can induce insulin sensitivity in diabetic milieu: a mechanistic review. Life Sci. 2020;240: 117090.</Citation><ArticleIdList><ArticleId IdType="pubmed">31765648</ArticleId></ArticleIdList></Reference><Reference><Citation>Marx N, Federici M, Sch&#xfc;tt K, M&#xfc;ller-Wieland D, Ajjan RA, Antunes MJ, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). Eur Heart J. 2023;44:4043&#x2013;140.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622663</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B&#xf6;hm M, et al. 2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2023;44:3627&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">37622666</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider CA, Pfister R. Treatment of heart failure with preserved ejection fraction with SGLT2 inhibitors: new therapy standard? Herz. 2022;47:395&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">36018379</ArticleId></ArticleIdList></Reference><Reference><Citation>Moellmann J, Klinkhammer BM, Droste P, Kappel B, Haj-Yehia E, Maxeiner S, et al. Empagliflozin improves left ventricular diastolic function of db/db mice. Biochimica et Biophysica Acta (BBA). 2020;1866: 165807.</Citation><ArticleIdList><ArticleId IdType="pubmed">32353614</ArticleId></ArticleIdList></Reference><Reference><Citation>J&#xfc;nger C, Prochaska JH, Gori T, Schulz A, Binder H, Daiber A, et al. Rationale and design of the effects of EMpagliflozin on left ventricular DIAstolic function in diabetes (EmDia) study. J Cardiovasc Med. 2022;23:191.</Citation><ArticleIdList><ArticleId IdType="pubmed">34939776</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019;393:31&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">30424892</ArticleId></ArticleIdList></Reference><Reference><Citation>Packer M. SGLT2 inhibitors produce cardiorenal benefits by promoting adaptive cellular reprogramming to induce a state of fasting mimicry: a paradigm shift in understanding their mechanism of action. Diabetes Care. 2020;43:508&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pubmed">32079684</ArticleId></ArticleIdList></Reference><Reference><Citation>Alberts B, Johnson A, Lewis J, Raff M, Roberts K, Walter P. The Lipid Bilayer. Mol Biol Cell 4th Ed [Internet]. Garland Science; 2002 [cited 2023 Oct 16]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK26871/</Citation></Reference><Reference><Citation>Bing RJ, Siegel A, Ungar I, Gilbert M. Metabolism of the human heart. Part II. Studies on fat, ketone and amino acid metabolism. Am J Med. 1954;16:504&#x2013;15.</Citation><ArticleIdList><ArticleId IdType="pubmed">13148192</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Vusse GJ, van Bilsen M, Glatz JF. Cardiac fatty acid uptake and transport in health and disease. Cardiovasc Res. 2000;45:279&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">10728348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishimoto K, Urade R, Ogawa T, Moriyama T. Nondestructive quantification of neutral lipids by thin-layer chromatography and laser-fluorescent scanning: suitable methods for &#x201c;lipidome&#x201d; analysis. Biochem Biophys Res Commun. 2001;281:657&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">11237708</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C, Wang K, Yang L, Liu R, Chu Y, Qin X, et al. Lipid metabolism in inflammation-related diseases. Analyst. 2018;143:4526&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">30128447</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R, Li B, Lam SM, Shui G. Integration of lipidomics and metabolomics for in-depth understanding of cellular mechanism and disease progression. J Genet Genomics. 2020;47:69&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">32178981</ArticleId></ArticleIdList></Reference><Reference><Citation>Lydic TA, Goo Y. Lipidomics unveils the complexity of the lipidome in metabolic diseases. Clin Transl Med. 2018;7: e4.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5786598</ArticleId><ArticleId IdType="pubmed">29374337</ArticleId></ArticleIdList></Reference><Reference><Citation>Lv J, Zhang L, Yan F, Wang X. Clinical lipidomics: a new way to diagnose human diseases. Clin Transl Med. 2018;7: e12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5923182</ArticleId><ArticleId IdType="pubmed">29704148</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner R, Baker D, Schwitter C, Neuhaus S, Hauptmann T, Post JM, et al. Four-dimensional trapped ion mobility spectrometry lipidomics for high throughput clinical profiling of human blood samples. Nat Commun. 2023;14:937.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9941096</ArticleId><ArticleId IdType="pubmed">36806650</ArticleId></ArticleIdList></Reference><Reference><Citation>Liebisch G, Fahy E, Aoki J, Dennis EA, Durand T, Ejsing CS, et al. Update on LIPID MAPS classification, nomenclature, and shorthand notation for MS-derived lipid structures. J Lipid Res. 2020;61:1539&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7707175</ArticleId><ArticleId IdType="pubmed">33037133</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon N, Friedman J, Hastie T, Tibshirani R. A sparse-group lasso. J Comput Graph Stat. 2013;22:231&#x2013;45.</Citation></Reference><Reference><Citation>Buch G, Schulz A, Schmidtmann I, Strauch K, Wild PS. Sparse group penalties for bi-level variable selection. Biom J. 2024;66: 2200334.</Citation><ArticleIdList><ArticleId IdType="pubmed">38747086</ArticleId></ArticleIdList></Reference><Reference><Citation>Buch G, Schulz A, Schmidtmann I, Strauch K, Wild PS. Interpretability of bi-level variable selection methods. Biom J. 2024;66: 2300063.</Citation><ArticleIdList><ArticleId IdType="pubmed">38519877</ArticleId></ArticleIdList></Reference><Reference><Citation>Obesity [Internet]. [cited 2025 Jan 30]. Available from: https://www.who.int/health-topics/obesity</Citation></Reference><Reference><Citation>Ren L, Li F, Tan X, Fan Y, Ke B, Zhang Y, et al. Abnormal plasma ceramides refine high-risk patients with worsening heart failure. Front Cardiovasc Med. 2023;10:1185595.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10339027</ArticleId><ArticleId IdType="pubmed">37456812</ArticleId></ArticleIdList></Reference><Reference><Citation>Shu H, Peng Y, Hang W, Li N, Zhou N, Wang DW. Emerging roles of ceramide in cardiovascular diseases. Aging Dis. 2022;13:232&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782558</ArticleId><ArticleId IdType="pubmed">35111371</ArticleId></ArticleIdList></Reference><Reference><Citation>Michelucci E, Rocchiccioli S, Gaggini M, Ndreu R, Berti S, Vassalle C. Ceramides and cardiovascular risk factors, inflammatory parameters and left ventricular function in AMI patients. Biomedicines. 2022;10:429.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8962314</ArticleId><ArticleId IdType="pubmed">35203637</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi RH, Tatum SM, Symons JD, Summers SA, Holland WL. Ceramides and other sphingolipids as drivers of cardiovascular disease. Nat Rev Cardiol. 2021;18:701&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8978615</ArticleId><ArticleId IdType="pubmed">33772258</ArticleId></ArticleIdList></Reference><Reference><Citation>Park LK, Garr Barry V, Hong J, Heebink J, Sah R, Peterson LR. Links between ceramides and cardiac function. Curr Opin Lipidol. 2022;33:47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8702478</ArticleId><ArticleId IdType="pubmed">34889803</ArticleId></ArticleIdList></Reference><Reference><Citation>Sokolowska E, Blachnio-Zabielska A. The Role of Ceramides in Insulin Resistance. Front Endocrinol [Internet]. 2019 [cited 2024 Feb 16];10. Available from: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2019.00577</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6712072</ArticleId><ArticleId IdType="pubmed">31496996</ArticleId></ArticleIdList></Reference><Reference><Citation>Knuplez E, Marsche G. An Updated Review of Pro- and Anti-Inflammatory Properties of Plasma Lysophosphatidylcholines in the Vascular System. Int J Mol Sci. 2020;21:4501.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7350010</ArticleId><ArticleId IdType="pubmed">32599910</ArticleId></ArticleIdList></Reference><Reference><Citation>Law S-H, Chan M-L, Marathe GK, Parveen F, Chen C-H, Ke L-Y. An updated review of lysophosphatidylcholine metabolism in human diseases. Int J Mol Sci. 2019. 10.3390/ijms20051149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6429061</ArticleId><ArticleId IdType="pubmed">30845751</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Veen JN, Kennelly JP, Wan S, Vance JE, Vance DE, Jacobs RL. The critical role of phosphatidylcholine and phosphatidylethanolamine metabolism in health and disease. Biochimica et Biophysica Acta (BBA). 2017;1859:1558&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">28411170</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomczyk MM, Dolinsky VW. The cardiac lipidome in models of cardiovascular disease. Metabolites. 2020;10:254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7344916</ArticleId><ArticleId IdType="pubmed">32560541</ArticleId></ArticleIdList></Reference><Reference><Citation>Hammad SM, Lopes-Virella MF. Circulating sphingolipids in insulin resistance, diabetes and associated complications. Int J Mol Sci. 2023;24: 14015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10531201</ArticleId><ArticleId IdType="pubmed">37762318</ArticleId></ArticleIdList></Reference><Reference><Citation>Kovilakath A, Wohlford G, Cowart LA. Circulating sphingolipids in heart failure. Front Cardiovasc Med. 2023;10:1154447.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10203217</ArticleId><ArticleId IdType="pubmed">37229233</ArticleId></ArticleIdList></Reference><Reference><Citation>Meikle TG, Huynh K, Giles C, Meikle PJ. Clinical lipidomics: realizing the potential of lipid profiling. J Lipid Res. 2021;62: 100127.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8528718</ArticleId><ArticleId IdType="pubmed">34582882</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler J, Packer M, Filippatos G, Ferreira JP, Zeller C, Schnee J, et al. Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction. Eur Heart J. 2022;43:416&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8825259</ArticleId><ArticleId IdType="pubmed">34878502</ArticleId></ArticleIdList></Reference><Reference><Citation>Anker SD, Butler J, Usman MS, Filippatos G, Ferreira JP, Bocchi E, et al. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-preserved. Nat Med. 2022;28:2512&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9800272</ArticleId><ArticleId IdType="pubmed">36471037</ArticleId></ArticleIdList></Reference><Reference><Citation>Catalyst Partner: Smarter screening with lipidomics | Heart Foundation. [cited 2025 Aug 15]; Available from: https://www.heartfoundation.org.au/catalyst/mcvd-risk</Citation></Reference><Reference><Citation>Association WM. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ. 2003;79:373.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2566407</ArticleId><ArticleId IdType="pubmed">11357217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>